Business Context and Reporting Period
Company: Akebia Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 12, 2019
Event: Entry into a Material Definitive Agreement (Item 1.01).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new securities offering agreement.
Material Changes and Agreements
- Agreement: Entered into an Amended and Restated Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co.
- Instrument: Common Stock, par value $0.00001 per share (Trading Symbol: AKBA).
- Method: "At the market" offering pursuant to Rule 415(a)(4).
- Commission: Cantor Fitzgerald will receive up to 3.0% of gross proceeds from share sales.
- Obligation: The Company has no obligation to sell any shares; the offering may be suspended or terminated by either party upon notice.
- Registration: Shares are registered under an existing automatic shelf registration statement (File No. 333-223585) effective March 12, 2018.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on future performance, or specific risk factors beyond standard securities law disclaimers. The document notes that the report does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful.
Investor Verification Checklist
- Verify the total number of shares authorized for sale under the existing shelf registration statement (File No. 333-223585).
- Monitor future filings for actual share sales and gross proceeds generated under this agreement.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination conditions and market restrictions.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to assess the necessity of this financing mechanism.